Video: Who Am I?| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: psoriasis

Predictive Value of Whole-Body MRI & Ultrasound Explored in EULAR Studies

Thomas R. Collins  |  July 13, 2017

Highlights from the 2017 EULAR Congress MADRID—Researchers say that whole-body MRI could yield an earlier diagnosis of spondyloarthropathy (SpA) in patients with early inflammatory joint symptoms, according to findings presented in a poster session at the Annual European Congress of Rheumatology (EULAR). The approach could lead to earlier treatment and better outcomes, they say. Investigators…

Filed under:Meeting Reports Tagged with:EULARimagingMRIUltrasound

Genes Connect Parkinson’s Disease to Autoimmune Diseases

Lara C. Pullen, PhD  |  July 3, 2017

A study has identified several common genetic pathways between Parkinson’s disease and autoimmune diseases. Specifically, researchers have used a genome-wide conjunctional analysis to identify 17 novel loci that overlap the conditions…

Filed under:Conditions Tagged with:Autoimmune diseasegenetic locigeneticsgenomeParkinson’s Disease

FDA Responds to New Drug Application for Baricitinib

Michele B. Kaufman, PharmD, BCGP  |  June 15, 2017

Oxycodone Tablets Submitted to FDA Filings for oxycodone tablets (Oxaydo) in both 10 and 15 mg doses have been accepted by the U.S. Food and Drug Administration (FDA).1 The submission is based on a pharmacokinetic study demonstrating bioequivalence to the reference drug, oxycodone hydrochloride (Roxicodone) tablets at a 15 mg dose. The product is an…

Filed under:AnalgesicsConditionsDrug Updates Tagged with:analgesicApprovalsbaricitinibDisease-modifying antirheumatic drugs (DMARDs)drugFDAopioidOxycodonePsoriatic ArthritisQualityRARheumatoid arthritisSafetysecukinumabupdate

Clinical Guidelines for Sjögren’s Syndrome Focus on Biologics, Fatigue, Inflammatory Musculoskeletal Pain

Kurt Ullman  |  June 15, 2017

The first clinical practice guidelines for Sjögren’s syndrome have been released, the culmination of an initiative by the Sjögren’s Syndrome Foundation.1 These standard-of-care recommendations are intended to provide consistency in practice patterns, inform coverage and reimbursement policies, lead to the design and implementation of educational programs, highlight the needs for future research and fill a…

Filed under:ConditionsOther Rheumatic ConditionsSjögren’s Disease Tagged with:BiologicsClinicaldrug therapyfatigueguidelineinflammatory musculoskeletal diseasePainpatient carerecommendationRheumatic DiseaseSjogren'sTreatment

U.S. Supreme Court Speeds Copycat Biologic Drugs to Market

Andrew Chung  |  June 13, 2017

WASHINGTON (Reuters)—The U.S. Supreme Court on Monday cut the time it will take for copycat versions of biologic drugs to get to the market in a pivotal ruling about an expensive class of medicines that can yield billions of dollars in sales for drug companies. The justices, in a 9–0 ruling, overturned a lower court…

Filed under:Biologics/DMARDsDrug Updates Tagged with:BiologicsBiologics & BiosimilarsBiosimilarsLegalSupreme CourtU.S. Supreme Court

Parkinson’s, Autoimmune Disorders May Share Genetic Common Ground

Joan Stephenson  |  June 12, 2017

NEW YORK (Reuters Health)—Parkinson’s disease and some autoimmune diseases may have genetic risk factors in common, raising the possibility that the immune system may influence Parkinson’s disease pathogenesis, new research suggests. The study, which analyzed data from genome-wide association studies, “showed a considerable genetic overlap between [Parkinson’s disease] and autoimmune diseases, in particular, type 1…

Filed under:Conditions Tagged with:Autoimmune diseasegenomeParkinson’s Disease

Ixekizumab Eases Psoriatic Arthritis when TNF Inhibitor Fails

Reuters Staff  |  June 1, 2017

NEW YORK (Reuters Health)—The selective interleukin-17A inhibitor ixekizumab improved signs and symptoms of active psoriatic arthritis (PsA) in patients who had failed prior biologic therapy in the phase 3 SPIRIT-P2 trial. The SPIRIT-P2 trial joins the earlier phase 3 SPIRIT-P1 trial, which showed that ixekizumab was safe and effective in PsA patients not previously treated…

Filed under:ConditionsDrug UpdatesPsoriatic Arthritis Tagged with:interleukin-17A inhibitorixekizumabphase 3 SPIRIT-P2 trialPsoriatic ArthritisTNF inhibitor

Infliximab-abda Becomes 5th Biosimilar Approved in the U.S. & Abaloparatide Approved for Osteoporosis

Michele B. Kaufman, PharmD, BCGP  |  May 22, 2017

The FDA has approved infliximab-abda, a biosimilar for treating multiple rheumatic diseases, as well as abaloparatide for treating postmenopausal women with osteoporosis…

Filed under:Biologics/DMARDsConditionsDrug UpdatesOsteoarthritis and Bone Disorders Tagged with:abaloparatideFDAFood and Drug Administrationinfliximabinfliximab-abdaOsteoporosis

Lightspring/shutterstock.com

The Immune Checkpoint Inhibitors Unleashed to Fight Cancer

Dana Direnzo, MD, Ami A. Shah, MD, MHS, Clifton O. Bingham III, MD, & Laura C. Cappelli, MD, MHS  |  May 17, 2017

A 53-year-old female presented to the clinic for severe polyarticular joint pain and was found to have a seronegative inflammatory arthritis. Six months before, she had completed 10 months of treatment for stage IV metastatic melanoma with the immune checkpoint inhibitors, nivolumab and ipilimumab, achieving complete remission of her cancer. She said that throughout her…

Filed under:ConditionsResearch Rheum Tagged with:adverse eventsArthritisCancerImmune checkpoint inhibitorsimmunotherapypatient careRemissionResearchrheumatologystudyTreatment

Alliance Working to Rein in Power of PBMs

Kathy Holliman  |  May 17, 2017

A coalition of patient and provider groups, including the ACR, is raising awareness about the effect of pharmacy benefit managers (PBMs) on patient care and the cost of prescription drugs. The Alliance for Transparent and Affordable Prescriptions, or ATAP, argues that too few restrictions have been placed on PBM transparency, and requirements for PBMs to…

Filed under:Legislation & AdvocacyProfessional Topics Tagged with:drug costspharmacy benefit managers (PBMs)The Alliance for Transparent and Affordable Prescriptions

  • « Previous Page
  • 1
  • …
  • 33
  • 34
  • 35
  • 36
  • 37
  • …
  • 55
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences